Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'CYP2C19' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 147 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Dojo, M; Azuma, T; Saito, T; Ohtani, M; Muramatsu, A; Kuriyama, M
      Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pyloriinfection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan

      DIGESTIVE AND LIVER DISEASE
    2. Hoskins, JM; Shenfield, GM; Gross, AS
      A modified HPLC method for rapid detection of moclobemide and its N-oxide metabolite in human urine

      JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES
    3. Wilson, JF; Weale, ME; Smith, AC; Gratrix, F; Fletcher, B; Thomas, MG; Bradman, N; Goldstein, DB
      Population genetic structure of variable drug response

      NATURE GENETICS
    4. Furuta, T; Shirai, N; Takashima, M; Xiao, F; Hanai, H; Nakagawa, K; Sugimura, H; Ohashi, K; Ishizaki, T
      Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin

      PHARMACOGENETICS
    5. Griese, EU; Ilett, KF; Kitteringham, NR; Eichelbaum, M; Powell, H; Spargo, RM; LeSouef, PN; Musk, AW; Minchin, RF
      Allele and genotype frequencies of polymorphic cytochromes P4502D6, 2C19 and 2E1 in Aborigines from Western Australia

      PHARMACOGENETICS
    6. Yamada, S; Onda, M; Kato, S; Matsuda, N; Matsuhisa, T; Yamada, N; Miki, M; Matsukura, N
      Genetic differences in CYP2C19 single nucleotide polymorphisms among four Asian populations

      JOURNAL OF GASTROENTEROLOGY
    7. Sakai, T; Aoyama, N; Kita, T; Sakaeda, T; Nishiguchi, K; Nishitora, Y; Hohda, T; Sirasaka, D; Tamura, T; Tanigawara, Y; Kasuga, M; Okumura, K
      CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects

      PHARMACEUTICAL RESEARCH
    8. Kita, T; Tanigawara, Y; Aoyama, N; Hohda, T; Saijoh, Y; Komada, F; Sakaeda, T; Okumura, K; Sakai, T; Kasuga, M
      CYP2C19 genotype related effect of omeprazole on intragastric pH and antimicrobial stability

      PHARMACEUTICAL RESEARCH
    9. Goldstein, JA
      Clinical relevance of genetic polymorphisms in the human CYP2C subfamily

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    10. Liu, ZQ; Cheng, ZN; Huang, SL; Chen, XP; Ou-Yang, DS; Jiang, CH; Zhou, HH
      Effect of the CYP2C19 oxidation polymorphism on fluoxetine metabolism in Chinese healthy subjects

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    11. Tamminga, WJ; Wemer, J; Oosterhuis, B; Wieling, J; Touw, DJ; de Zeeuw, RA; de Leij, LFMH; Jonkman, JHG
      Mephenytoin as a probe for CYP2C19 phenotyping: effect of sample storage, intra-individual reproducibility and occurrence of adverse events

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    12. Hagg, S; Spigset, O; Dahlqvist, R
      Influence of gender and oral contraceptives on CYP2D6 and CY2ZC19 activityin healthy volunteers

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    13. Baede-van Dijk, PA; Hugen, PWH; Verweij-van Wissen, CPWGM; Koopmans, PP; Burger, DM; Hekster, YA
      Analysis of variation in plasma concentrations of nelfinavir and its active metabolite M8 in HIV-positive patients

      AIDS
    14. Shu, Y; Cheng, ZN; Liu, ZQ; Wang, LS; Zhu, B; Huang, SL; Ou-Yang, DS; Zhou, HH
      Interindividual variations in levels and activities of cytochrome P-450 inliver microsomes of Chinese subjects

      ACTA PHARMACOLOGICA SINICA
    15. Carlsson, B; Olsson, G; Reis, M; Walinder, J; Nordin, C; Lundmark, J; Scordo, MG; Dahl, ML; Bengtsson, F; Ahlner, J
      Enantioselective analysis of citalopram and metabolites in adolescents

      THERAPEUTIC DRUG MONITORING
    16. Eap, CB; Bondolfi, G; Zullino, D; Bryois, C; Fuciec, M; Savary, L; Jonzier-Perey, M; Baumann, P
      Pharmacokinetic drug interaction potential of risperidone with cytochrome P450 isozymes as assessed by the dextromethorphan, the caffeine, and the mephenytoin test

      THERAPEUTIC DRUG MONITORING
    17. Hadama, A; Ieiri, I; Morita, T; Kimura, M; Urae, A; Irie, S; Kaneda, T; Mamiya, K; Tashiro, N; Higuchi, S; Otsubo, K
      P-hydroxylation of phenobarbital: Relationship to (s)-mephenytoin hydroxylation (CYP2C19) polymorphism

      THERAPEUTIC DRUG MONITORING
    18. Obach, RS; Zhang, QY; Dunbar, D; Kaminsky, LS
      Metabolic characterization of the major human small intestinal cytochrome P450S

      DRUG METABOLISM AND DISPOSITION
    19. Furuta, S; Kamada, E; Suzuki, T; Sugimoto, T; Kawabata, Y; Shinozaki, Y; Sano, H
      Inhibition of drug metabolism in human liver microsomes by nizatidine, cimetidine and omeprazole

      XENOBIOTICA
    20. Kappers, WA; Edwards, RJ; Murray, S; Boobis, AR
      Diazinon is activated by CYP2C19 in human liver

      TOXICOLOGY AND APPLIED PHARMACOLOGY
    21. Laine, K; Anttila, M; Nyman, L; Wahlberg, A; Bertilsson, L
      CYP2C19 polymorphism is not important for the in vivo metabolism of selegiline

      EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    22. Tamminga, WJ; Wemer, J; Oosterhuis, B; Brakenhoff, JPG; Gerrits, MGF; de Zeeuw, RA; de Leij, LFMH; Jonkman, JHG
      An optimized methodology for combined phenotyping and genotyping on CYP2D6and CYP2C19

      EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    23. Giancarlo, GM; Venkatakrishnan, K; Granda, BW; von Moltke, LL; Greenblatt, DJ
      Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole, and ticlopidine

      EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    24. Furuta, T; Shirai, N; Xiao, F; Ohashi, K; Ishizaki, T
      Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    25. Zhou, HH
      CYP2C19 genotype determines enzyme activity and inducibility of S-mephenytoin hydroxylase

      CLINICA CHIMICA ACTA
    26. Oliw, EH; Stark, K; Bylund, J
      Oxidation of prostaglandin H-2 and prostaglandin H-2 analogues by human cytochromes P450: analysis of omega-side chain hydroxy metabolites and four steroisomers of 5-hydroxyprostaglandin I-1 by mass spectrometry

      BIOCHEMICAL PHARMACOLOGY
    27. Kirchheiner, J; Brosen, K; Dahl, ML; Gram, LF; Kasper, S; Roots, I; Sjoqvist, F; Spina, E; Brockmoller, J
      CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages

      ACTA PSYCHIATRICA SCANDINAVICA
    28. Zhou, HH; Liu, ZO
      Ethnic differences in drug metabolism

      CLINICAL CHEMISTRY AND LABORATORY MEDICINE
    29. Clark, D; Morgan, A; Hananeia, L; Coulter, D; Olds, R
      Drug metabolism genotypes and their association with adverse drug reactions in selected populations: a pilot study of methodology

      PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
    30. Thijssen, HHW; Verkooijen, IWC; Frank, HLL
      The possession of the CYP2C9*3 allele is associated with low dose requirement of acenocoumarol

      PHARMACOGENETICS
    31. Gaedigk, A
      Interethnic differences of drug-metabolizing enzymes

      INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
    32. Khaliq, Y; Gallicano, K; Seguin, I; Fyke, K; Carignan, G; Bulman, D; Badley, A; Cameron, DW
      Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus-infected patients with chronic liver disease

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    33. Ford, GA; Wood, SM; Daly, AK
      CYP2D6 and CYP2C19 genotypes of patients with terodiline cardiotoxicity identified through the yellow card system

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    34. Williams, ML; Bhargava, P; Cherrouk, I; Marshall, JL; Flockhart, DA; Wainer, IW
      A discordance of the cytochrome P4502C19 genotype and phenotype in patients with advanced cancer

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    35. Tassaneeyakul, W; Tassaneeyakul, W; Vannaprasaht, S; Yamazoe, Y
      Formation of omeprazole sulphone but not 5-hydroxyomeprazole is inhibited by grapefruit juice

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    36. Egan, LJ; Murray, JA
      New perspectives in gastric acid suppression: Genetic polymorphisms predict the efficacy of proton pump inhibitors

      DIGESTIVE DISEASES
    37. Britzi, M; Bialer, M; Arcavi, L; Shachbari, A; Kapitulnik, J; Soback, S
      Genetic polymorphism of CYP2D6 and CYP2C19 metabolism determined by phenotyping Israeli ethnic groups

      THERAPEUTIC DRUG MONITORING
    38. Eap, CB; Bender, S; Gastpar, M; Fischer, W; Haarmann, C; Powell, K; Jonzier-Perey, M; Cochard, N; Baumann, P
      Steady state plasma levels of the enantiomers of trimipramine and of its metabolites in CYP2D6-, CYP2C19-and CYP3A4/5-phenotyped patients

      THERAPEUTIC DRUG MONITORING
    39. Abelo, A; Andersson, TB; Antonsson, M; Naudot, AK; Skanberg, I; Weidolf, L
      Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes

      DRUG METABOLISM AND DISPOSITION
    40. Fukuda, T; Nishida, Y; Zhou, Q; Yamamoto, I; Kondo, S; Azuma, J
      The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population

      EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    41. Mamiya, K; Hadama, A; Yukawa, E; Ieiri, I; Otsubo, K; Ninomiya, H; Tashiro, N; Higuchi, S
      CYP2C19 polymorphism effect on phenobarbitone - Pharmacokineties in Japanese patients with epilepsy: analysis by population pharmacokinetics

      EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    42. Chau, TKH; Murakami, S; Kawai, B; Nasu, K; Kubota, T; Ohnishi, A
      Genotype analysis of the CYP2C19 gene in HCV-seropositive patients with cirrhosis and hepatocellular carcinoma

      LIFE SCIENCES
    43. Xie, HG
      Genetic variations of S-mephenytoin 4 '-hydroxylase (CYP2C19) in the Chinese population

      LIFE SCIENCES
    44. Stormer, ES; von Moltke, LL; Greenblatt, DJ
      Scaling drug biotransformation data from cDNA-expressed cytochrome P-450 to human liver: A comparison of relative activity factors and human liver abundance in studies of mirtazapine metabolism

      JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
    45. Laine, K; Tybring, G; Bertilsson, L
      No sex-related differences but significant inhibition by oral contraceptives of CYP2C19 activity as measured by the probe drugs mephenytoin and omeprazole in healthy Swedish white subjects

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    46. Itoh, K; Inoue, K; Nakao, H; Yanagiwara, S; Tada, H; Suzuki, T
      Polymerase chain reaction-single-strand conformation polymorphism based determination of two major genetic defects responsible for a phenotypic polymorphism of cytochrome P450 (CYP) 2C19 in the Japanese population

      ANALYTICAL BIOCHEMISTRY
    47. Xie, HG; Stein, CM; Kim, RB; Wilkinson, GR; Flockhart, DA; Wood, AJJ
      Allelic, genotypic and phenotypic distributions of S-mephenytoin 4 '-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world

      PHARMACOGENETICS
    48. Kaneko, A; Lum, JK; Yaviong, J; Takahashi, N; Ishizaki, T; Bertilsson, L; Kobayakawa, T; Bjorkman, A
      High and variable frequencies of CYP2C19 mutations: medical consequences of poor drug metabolism in Vanuatu and other Pacific islands

      PHARMACOGENETICS
    49. Kaneko, A; Bergqvist, Y; Taleo, G; Kobayakawa, T; Ishizaki, T; Bjorkman, A
      Proguanil disposition and toxicity in malaria patients from Vanuatu with high frequencies of CYP2C19 mutations

      PHARMACOGENETICS
    50. Griese, EU; Lapple, F; Eichelbaum, M
      Detection of CYP2C19 alleles*1,*2 and*3 by multiplex polymerase chain reaction

      PHARMACOGENETICS
    51. Rost, KL; Fuhr, U; Thomsen, T; Zaigler, M; Brockmoller, J; Bohnemeier, H; Roots, I
      Omeprazole weakly inhibits CYP1A2 activity in man

      INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
    52. Aoyama, N; Tanigawara, Y; Kita, T; Sakai, T; Shirakawa, K; Shirasaka, D; Kodama, F; Okumura, K; Kasuga, M
      Sufficient effect of 1-week omeprazole and amoxicillin dual treatment for Helicobacter pylori eradication in cytochrome P4502C19 poor metabolizers

      JOURNAL OF GASTROENTEROLOGY
    53. Itoh, K; Inoue, K; Yanagiwara, S; Kyoya, H; Suzuki, T
      A rapid and simple detection of genetic defects responsible for the phenotypic polymorphism of cytochrome P450 2C19

      BIOLOGICAL & PHARMACEUTICAL BULLETIN
    54. Mihara, K; Svensson, USH; Tybring, G; Hai, TN; Bertilsson, L; Ashton, M
      Stereospecific analysis of omeprazole supports artemisinin as a potent inducer of CYP2C19

      FUNDAMENTAL & CLINICAL PHARMACOLOGY
    55. Bathum, L; Skjelbo, E; Mutabingwa, TK; Madsen, H; Horder, M; Brosen, K
      Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    56. Xie, HG; Kim, RB; Stein, CM; Wilkinson, GR; Wood, AJJ
      Genetic polymorphism of (S)-mephenytoin 4 '-hydroxylation in populations of African descent

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    57. Xu, ZH; Wang, W; Zhao, XJ; Huang, SL; Zhu, B; He, N; Shu, Y; Liu, ZQ; Zhou, HH
      Evidence for involvement of polymorphic CYP2C 19 and 2C9 in the N-demethylation of sertraline in human liver microsomes

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    58. Coller, JK; Somogyi, AA; Bochner, F
      Comparison of (S)-mephenytoin and proguanil oxidation in vitro: contribution of several CYP isoforms

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    59. Tateishi, T; Kumai, T; Watanabe, M; Nakura, H; Tanaka, M; Kobayashi, S
      Ticlopidine decreases the in vivo activity of CYP2C19 as measured by omeprazole metabolism

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    60. Brynne, N; Bottiger, Y; Hallen, B; Bertilsson, L
      Tolterodine does not affect the human in vivo metabolism of the probe drugs caffeine, debrisoquine and omeprazole

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    61. Kimura, M; Ieiri, I; Wada, Y; Mamiya, K; Urae, A; Iimori, E; Sakai, T; Otsubo, K; Higuchi, S
      Reliability of the omeprazole hydroxylation index for CYP2C19 phenotyping:possible effect of age, liver disease and length of therapy

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    62. Coutts, RT; Urichuk, LJ
      Polymorphic cytochromes P450 and drugs used in psychiatry

      CELLULAR AND MOLECULAR NEUROBIOLOGY
    63. Kovacs, P; Edwards, DJ; Lalka, D; Scheiwe, WM; Stoeckel, K
      High-dose omeprazole: Use of a multiple-dose study design to assess bioequivalence and accuracy of CYP2C19 phenotyping

      THERAPEUTIC DRUG MONITORING
    64. Tamminga, WJ; Wemer, J; Oosterhuis, B; Wieling, J; Wilffert, B; de Leij, LFMH; de Zeeuw, RA; Jonkman, JHG
      CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences

      EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    65. Zhou, Q; Yamamoto, I; Fukuda, T; Ohno, M; Sumida, A; Azuma, J
      CYP2C19 genotypes and omeprazole metabolism after single and repeated dosing when combined with clarithromycin

      EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    66. Aynacioglu, AS; Sachse, C; Bozkurt, A; Kortunay, S; Nacak, M; Schroder, T; Kayaalp, SO; Roots, I; Brockmoller, J
      Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6in the Turkish population

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    67. Furuta, T; Ohashi, K; Kosuge, K; Zhao, XJ; Takashima, M; Kimura, M; Nishimoto, M; Hanai, H; Kaneko, E; Ishizaki, T
      C Upsilon P2C19 genotype status and effect of omeprazole on intragastric pH in humans

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    68. Terao, T; Ohmori, O; Shinkai, T
      A puzzling case of seizures and visual hallucinations during clomipramine treatment with a high dose but causing a low serum concentration

      ACTA PSYCHIATRICA SCANDINAVICA
    69. KUSUMOTO M; UENO K; TANAKA K; TAKEDA K; MASHIMO K; KAMEDA T; FUJIMURA Y; SHIBAKAWA M
      LACK OF PHARMACOKINETIC INTERACTION BETWEEN MEXILETINE AND OMEPRAZOLE

      The Annals of pharmacotherapy
    70. YAICH M; POPON M; MEDARD Y; AIGRAIN EJ
      IN-VITRO CYTOCHROME-P450 DEPENDENT METABOLISM OF OXYBUTYNIN TO N-DEETHYLOXYBUTYNIN IN HUMANS

      Pharmacogenetics
    71. IBEANU GC; BLAISDELL J; GHANAYEM BI; BEYELER C; BENHAMOU S; BOUCHARDY C; WILKINSON GR; DAYER P; DALY AK; GOLDSTEIN JA
      AN ADDITIONAL DEFECTIVE ALLELE, CYP2C19-ASTERISK-5, CONTRIBUTES TO THE S-MEPHENYTOIN POOR METABOLIZER PHENOTYPE IN CAUCASIANS

      Pharmacogenetics
    72. MAMIYA K; IEIRI I; MIYAHARA S; IMAI J; FURUUMI H; FUKUMAKI Y; NINOMIYA H; TASHIRO N; YAMADA H; HIGUCHI S
      ASSOCIATION OF POLYMORPHISMS IN THE CYTOCHROME-P450 (CYP) 2C19 AND 2C18 GENES IN JAPANESE EPILEPTIC PATIENTS

      Pharmacogenetics
    73. Yamada, H; Dahl, ML; Viitanen, M; Winblad, B; Sjoqvist, F; Lannfelt, L
      No association between familial Alzheimer disease and cytochrome P450 polymorphisms

      ALZHEIMER DISEASE & ASSOCIATED DISORDERS
    74. VANAGTMAEL MA; VANDERGRAAF CAA; DIEN TK; KOOPMANS RP; VANBOXTEL CJ
      THE CONTRIBUTION OF THE ENZYMES CYP2D6 AND CYP2C19 IN THE DEMETHYLATION OF ARTEMETHER IN HEALTHY-SUBJECTS

      European journal of drug metabolism and pharmacokinetics
    75. WATANABE M; IWAHASHI K; KUGOH T; SUWAKI H
      THE RELATIONSHIP BETWEEN PHENYTOIN PHARMACOKINETICS AND THE CYP2C19 GENOTYPE IN JAPANESE EPILEPTIC PATIENTS

      Clinical neuropharmacology
    76. HOSKINS JM; SHENFIELD GM; GROSS AS
      RELATIONSHIP BETWEEN PROGUANIL METABOLIC RATIO AND CYP2C19 GENOTYPE IN A CAUCASIAN POPULATION

      British journal of clinical pharmacology
    77. BROSEN K
      DIFFERENCES IN INTERACTIONS OF SSRIS

      International clinical psychopharmacology
    78. HUANG SL; XIE HG; WANG W; XU ZH; JIANG CH; ZHOU HH
      DETERMINATION OF S R RATIO OF MEPHENYTOIN IN HUMAN URINE BY CHIRAL HPLC AND ULTRAVIOLET DETECTION AND ITS COMPARISON WITH GAS-CHROMATOGRAPHY/

      Zhongguo yaoli xuebao
    79. KIMURA M; IEIRI I; MAMIYA K; URAE F; HIGUCHI S
      GENETIC-POLYMORPHISM OF CYTOCHROME P450S, CYP2C19, AND CYP2C9 IN A JAPANESE POPULATION

      Therapeutic drug monitoring
    80. BATHUM L; HANSEN TS; HORDER M; BROSEN K
      A DUAL-LABEL OLIGONUCLEOTIDE LIGATION ASSAY FOR DETECTION OF THE CYP2C19-ASTERISK-1, CYP2C19-ASTERISK-2, AND CYP2C19-ASTERISK-3 ALLELES INVOLVING TIME-RESOLVED FLUOROMETRY

      Therapeutic drug monitoring
    81. SAGAR M; SEENSALU R; TYBRING G; DAHL ML; BERTILSSON L
      CYP2C19 GENOTYPE AND PHENOTYPE DETERMINED WITH OMEPRAZOLE IN PATIENTSWITH ACID-RELATED DISORDERS WITH AND WITHOUT HELICOBACTER-PYLORI INFECTION

      Scandinavian journal of gastroenterology
    82. YAMADA H; DAHL ML; LANNFELT L; VIITANEN M; WINBLAD B; SJOQVIST F
      CYP2D6 AND CYP2C19 GENOTYPES IN AN ELDERLY SWEDISH POPULATION

      European Journal of Clinical Pharmacology
    83. WANWIMOLRUK S; BHAWAN S; COVILLE PF; CHALCROFT SCW
      GENETIC-POLYMORPHISM OF DEBRISOQUINE (CYP2D6) AND PROGUANIL (CYP2C19)IN SOUTH-PACIFIC POLYNESIAN POPULATIONS

      European Journal of Clinical Pharmacology
    84. Rasmussen, BB; Nielsen, TL; Brosen, K
      Fluvoxamine inhibits the CYP2C19-catalysed metabolism of proguanil in vitro

      EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    85. Arimori, K; Yasuda, K; Katsuki, H; Nakano, M
      Pharmacokinetic differences between lansoprazole enantiomers in rats

      JOURNAL OF PHARMACY AND PHARMACOLOGY
    86. Mamiya, K; Ieiri, I; Shimamoto, J; Yukawa, E; Imai, J; Ninomiya, H; Yamada, H; Otsubo, K; Higuchi, S; Tashiro, N
      The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: Studies in stereoselective hydroxylation and population pharmacokinetics

      EPILEPSIA
    87. SVENSSON USH; ASHTON M; HAI TN; BERTILSSON L; HUONG DX; VANHUONG N; NIEU NT; SY ND; LYKKESFELDT J; CONG LD
      ARTEMISININ INDUCES OMEPRAZOLE METABOLISM IN HUMAN-BEINGS

      Clinical pharmacology and therapeutics
    88. JUNG F; GRIFFIN KJ; SONG W; RICHARDSON TH; YANG M; JOHNSON EF
      IDENTIFICATION OF AMINO-ACID SUBSTITUTIONS THAT CONFER A HIGH-AFFINITY FOR SULFAPHENAZOLE BINDING AND A HIGH CATALYTIC EFFICIENCY FOR WARFARIN METABOLISM TO P450 2C19

      Biochemistry (Easton)
    89. KUBOTA T; HIBI N; CHIBA K
      LINKAGE OF MUTANT ALLELES OF CYP2C18 AND CYP2C19 IN A JAPANESE POPULATION

      Biochemical pharmacology
    90. STRESSER DM; KUPFER D
      PROSUBSTRATES OF CYP3A4, THE MAJOR HUMAN HEPATIC CYTOCHROME-P450 - TRANSFORMATION INTO SUBSTRATES BY OTHER P450 ISOFORMS

      Biochemical pharmacology
    91. KLOSE TS; IBEANU GC; GHANAYEM BI; PEDERSEN LG; LI LP; HALL SD; GOLDSTEIN JA
      IDENTIFICATION OF RESIDUE-286 AND RESIDUE-289 AS CRITICAL FOR CONFERRING SUBSTRATE-SPECIFICITY OF HUMAN CYP2C9 FOR DICLOFENAC AND IBUPROFEN

      Archives of biochemistry and biophysics (Print)
    92. LASKER JM; WESTER MR; ARAMSOMBATDEE E; RAUCY JL
      CHARACTERIZATION OF CYP2C19 AND CYP2C9 FROM HUMAN LIVER - RESPECTIVE ROLES IN MICROSOMAL TOLBUTAMIDE, S-MEPHENYTOIN, AND OMEPRAZOLE HYDROXYLATIONS

      Archives of biochemistry and biophysics
    93. MORINOBU S; TANAKA T; KAWAKATSU S; TOTSUKA S; KOYAMA E; CHIBA K; ISHIZAKI T; KUBOTA T
      EFFECTS OF GENETIC-DEFECTS IN THE CYP2C19 GENE ON THE N-DEMETHYLATIONOF IMIPRAMINE, AND CLINICAL OUTCOME OF IMIPRAMINE THERAPY

      PSYCHIATRY AND CLINICAL NEUROSCIENCES
    94. TYRING G; NORDIN J; BERGMAN T; BERTILSSON L
      AN S-MEPHENYTOIN CYSTEINE CONJUGATE IDENTIFIED IN URINE OF EXTENSIVE BUT NOT OF POOR METABOLIZERS OF S-MEPHENYTOIN

      Pharmacogenetics
    95. RUAS JL; LECHNER MC
      ALLELE FREQUENCY OF CYP2C19 IN A PORTUGUESE POPULATION

      Pharmacogenetics
    96. XIE HG; HUANG SL; XU ZH; XIAO XS; HE N; ZHOU HH
      EVIDENCE FOR THE EFFECT OF GENDER ON ACTIVITY OF (S)-MEPHENYTOIN 4'-HYDROXYLASE (CYP2C19) IN A CHINESE POPULATION

      Pharmacogenetics
    97. XIE HG; HUANG SL; XU ZH; XIAO XS; HE N; ZHOU HH
      EVIDENCE FOR THE EFFECT OF GENDER ON ACTIVITY OF (S)-MEPHENYTOIN 4'-HYDROXYLASE (CYP2C19) IN A CHINESE POPULATION

      Pharmacogenetics
    98. BENHAMOU S; BOUCHARDY C; DAYER P
      LUNG-CANCER RISK IN RELATION TO MEPHENYTOIN HYDROXYLATION ACTIVITY

      Pharmacogenetics
    99. BENHAMOU S; BOUCHARDY C; DAYER P
      LUNG-CANCER RISK IN RELATION TO MEPHENYTOIN HYDROXYLATION ACTIVITY

      Pharmacogenetics
    100. ROCHAT B; AMEY M; GILLET M; MEYER UA; BAUMANN P
      IDENTIFICATION OF 3 CYTOCHROME-P450 ISOZYMES INVOLVED IN N-DEMETHYLATION OF CITALOPRAM ENANTIOMERS IN HUMAN LIVER-MICROSOMES

      Pharmacogenetics


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 20/10/20 alle ore 23:08:44